Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Helfand

Showing results (21-30 of 39) with videos related to

Pageof 4
Sort By:
The Journal of Infectious Diseases|November 19, 2003
Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated miceUsha Stiefel, Nicole J Pultz, Jaana Harmoinen, et al.
American Journal of Infection Control|June 14, 2003
Role of fecal incontinence in contamination of the environment with vancomycin-resistant enterococciRichard A Mayer, Rula C Geha, Marion S Helfand, et al.
Biochemistry|November 19, 2003
Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallographyMarion S Helfand, Monica A Totir, Marianne P Carey, et al.
The Journal of Biological Chemistry|October 10, 2003
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130Marion S Helfand, Christopher R Bethel, Andrea M Hujer, et al.
Biochemistry|July 17, 2007
Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamaseMonica A Totir, Marion S Helfand, Marianne P Carey, et al.
Psychopharmacology|May 21, 2009
The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progressSandeep Kumar, Patrizia Porcu, David F Werner, et al.
Biochemistry|September 28, 2006
Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediatesMonica A Totir, Pius S Padayatti, Marion S Helfand, et al.
Biochemistry|June 28, 2007
Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitorsMarion S Helfand, Magdalena A Taracila, Monica A Totir, et al.
The Journal of Biological Chemistry|August 2, 2005
High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamasePius S Padayatti, Marion S Helfand, Monica A Totir, et al.
Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 1, 1996
Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosisR S Wallis, M S Helfand, C C Whalen, et al.
Pageof 4

Showing results (21-30 of 39) with videos related to

Sort By:
Pageof 4
The Journal of Infectious Diseases|November 19, 2003
Oral administration of beta-lactamase preserves colonization resistance of piperacillin-treated miceUsha Stiefel, Nicole J Pultz, Jaana Harmoinen, et al.
American Journal of Infection Control|June 14, 2003
Role of fecal incontinence in contamination of the environment with vancomycin-resistant enterococciRichard A Mayer, Rula C Geha, Marion S Helfand, et al.
Biochemistry|November 19, 2003
Following the reactions of mechanism-based inhibitors with beta-lactamase by Raman crystallographyMarion S Helfand, Monica A Totir, Marianne P Carey, et al.
The Journal of Biological Chemistry|October 10, 2003
Understanding resistance to beta-lactams and beta-lactamase inhibitors in the SHV beta-lactamase: lessons from the mutagenesis of SER-130Marion S Helfand, Christopher R Bethel, Andrea M Hujer, et al.
Biochemistry|July 17, 2007
Sulbactam forms only minimal amounts of irreversible acrylate-enzyme with SHV-1 beta-lactamaseMonica A Totir, Marion S Helfand, Marianne P Carey, et al.
Psychopharmacology|May 21, 2009
The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of progressSandeep Kumar, Patrizia Porcu, David F Werner, et al.
Biochemistry|September 28, 2006
Effect of the inhibitor-resistant M69V substitution on the structures and populations of trans-enamine beta-lactamase intermediatesMonica A Totir, Pius S Padayatti, Marion S Helfand, et al.
Biochemistry|June 28, 2007
Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitorsMarion S Helfand, Magdalena A Taracila, Monica A Totir, et al.
The Journal of Biological Chemistry|August 2, 2005
High resolution crystal structures of the trans-enamine intermediates formed by sulbactam and clavulanic acid and E166A SHV-1 {beta}-lactamasePius S Padayatti, Marion S Helfand, Monica A Totir, et al.
Tubercle and Lung Disease : the Official Journal of the International Union Against Tuberculosis and Lung Disease|December 1, 1996
Immune activation, allergic drug toxicity and mortality in HIV-positive tuberculosisR S Wallis, M S Helfand, C C Whalen, et al.
Pageof 4